VIENNA—Latest research on breast cancer prevention was reported at the 20125 St Gallen breast cancer conference in a session concluded by Jack Cuzick, PhD, Director of the Wolfson Institute of Preventive Medicine and Head of the Centre for Cancer...
ORLANDO—Adjuvant chemotherapy was found to extend life in patients with locally advanced bladder cancer in research reported to the 2015 Genitourinary Cancers Symposium. Matt Galsky MD from the Tisch Cancer Institute, Icahn School of Medicine at...
SAN FRANCISCO—The ability of cancer cells to evolve clonally into molecularly distinct strands needs to be considered when selecting targeted therapies to treat renal cancer, according to Dr Tom Powles MBBS, MRCP, MD speaking at the ASCO GU Cancers...
SAN FRANCISCO—New research has shown the alpha-emitting drug radium 233 to be a “benign” therapy with no major toxicities — while effectively targeting bone metastatic disease and increasing overall survival in patients with castration-resistant...
SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metastatic castration-resistant prostate cancer was...
Clear-cell renal cell cancer: first molecular prognostic marker also brings scope for drug targeting
SAN FRANCISCO— A recently discovered molecular prognostic biomarker for clear-cell renal cell cancer has been validated and shown to indicate a four-fold increase in risk of adverse cancer-specific survival and tumor recurrence. Dr. Ari Hakimi MD...
SAN FRANCISCO— Plasma and tumor biomarkers including FGF, C-KIT and VEG-F were found to yield prognostic information which could help guide therapies, according to research findings presented at the 2014 ASCO Genitourinary Cancers Conference...
SAN FRANCISCO—The length of time from nephrectomy up until the diagnosis of metastatis has been confirmed as prognostic for patients whose renal cell carcinoma was treated with targeted therapies — just as it is in patients overall — according to a...
SAN FRANCISCO— Gleason score at initial diagnosis was not predictive of response to abiraterone in patients with metastatic castration-resistant prostate cancer in a pooled analysis of three trials of abiraterone acetate therapy presented at the...
SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen deprivation therapy — with enzalutamide — with a PSA decline of at...
SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Symposium. Daniel Petrylak MD of Yale University Medical Center in...
SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “abiraterone-like” agent in comparison with placebo —...